Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHST BioHarvest Sciences	$7.20 -6.0%	$6.35	$4.66 ▼ $7.86	$118.26M	0.58	16,749 shs	7,872 shs
ORKA Oruka Therapeutics	$12.56 -2.4%	$10.28	$5.49 ▼ $31.13	$470.26M	-0.38	221,429 shs	131,591 shs
PRTC PureTech Health	$19.61 +1.9%	$17.39	$13.30 ▼ $28.79	$471.01M	1.15	4,702 shs	842 shs
RGNX REGENXBIO	$9.27 -9.1%	$8.45	$5.04 ▼ $15.36	$464.98M	1.09	926,730 shs	797,849 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHST BioHarvest Sciences	0.00%	+3.45%	+10.77%	+21.21%	+719,999,900.00%
ORKA Oruka Therapeutics	0.00%	-0.16%	+24.85%	+5.63%	+1,255,999,900.00%
PRTC PureTech Health	0.00%	+3.89%	+14.54%	+9.02%	-34.19%
RGNX REGENXBIO	0.00%	-3.54%	+4.27%	+32.43%	-25.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	2.9205 of 5 stars	3.6	0.0	0.0	0.0	3.4	2.5	0.6
PRTC PureTech Health	2.0652 of 5 stars	3.8	3.0	0.0	0.0	2.7	0.0	0.0
RGNX REGENXBIO	4.2789 of 5 stars	3.4	2.0	0.0	4.6	2.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHST BioHarvest Sciences	3.00	Buy	$13.67	89.81% Upside
ORKA Oruka Therapeutics	3.20	Buy	$40.38	221.46% Upside
PRTC PureTech Health	3.50	Strong Buy	$45.00	129.47% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	241.15% Upside

Current Analyst Ratings Breakdown

Latest BHST, PRTC, ORKA, and RGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
5/22/2025	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/22/2025	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$44.00
5/15/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $40.00
5/5/2025	BHST BioHarvest Sciences	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/17/2025	RGNX REGENXBIO	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00
4/8/2025	BHST BioHarvest Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
3/20/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $52.00
3/18/2025	RGNX REGENXBIO	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
3/17/2025	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHST BioHarvest Sciences	$27.70M	4.27	N/A	N/A	($1.08) per share	-6.67
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	$4.32M	109.16	N/A	N/A	$16.94 per share	1.16
RGNX REGENXBIO	$156.72M	2.97	N/A	N/A	$7.09 per share	1.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHST BioHarvest Sciences	-$12.56M	-$0.50	N/A	N/A	N/A	-76.65%	N/A	-85.16%	8/14/2025 (Estimated)
ORKA Oruka Therapeutics	-$5.34M	-$4.51	N/A	N/A	N/A	N/A	-24.96%	-21.22%	7/30/2025 (Estimated)
PRTC PureTech Health	-$65.70M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/30/2025 (Estimated)
RGNX REGENXBIO	-$263.49M	-$3.11	N/A	N/A	N/A	-283.19%	-70.65%	-41.68%	8/7/2025 (Estimated)

Latest BHST, PRTC, ORKA, and RGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	BHST BioHarvest Sciences	-$0.15	-$0.13	+$0.02	-$0.13	$8.93 million	$7.64 million
5/14/2025	Q1 2025	ORKA Oruka Therapeutics	-$0.57	-$0.40	+$0.17	-$0.40	N/A	N/A
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
3/31/2025	Q4 2024	BHST BioHarvest Sciences	-$0.12	-$0.17	-$0.05	-$0.17	$7.24 million	$7.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHST BioHarvest Sciences	N/A	0.80	0.48
ORKA Oruka Therapeutics	N/A	22.89	22.89
PRTC PureTech Health	N/A	3.68	N/A
RGNX REGENXBIO	N/A	3.05	3.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHST BioHarvest Sciences	N/A
ORKA Oruka Therapeutics	56.44%
PRTC PureTech Health	0.04%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
BHST BioHarvest Sciences	N/A
ORKA Oruka Therapeutics	24.69%
PRTC PureTech Health	5.30%
RGNX REGENXBIO	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHST BioHarvest Sciences	N/A	16.43 million	N/A	N/A
ORKA Oruka Therapeutics	N/A	37.44 million	27.07 million	N/A
PRTC PureTech Health	100	24.02 million	22.67 million	Not Optionable
RGNX REGENXBIO	370	50.16 million	43.04 million	Optionable

BHST, PRTC, ORKA, and RGNX Headlines

Recent News About These Companies

REGENXBIO (NASDAQ:RGNX) Stock Price Up 6.1% - What's Next?

June 11, 2025 | marketbeat.com

REGENXBIO's (RGNX) "Buy" Rating Reiterated at Chardan Capital

June 11, 2025 | americanbankingnews.com

A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts

June 9, 2025 | benzinga.com

REGENXBIO's (RGNX) Buy Rating Reaffirmed at Chardan Capital

June 9, 2025 | marketbeat.com

REGENXBIO Inc. (NASDAQ:RGNX) Receives $31.63 Consensus PT from Analysts

June 8, 2025 | americanbankingnews.com

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

June 6, 2025 | seekingalpha.com

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update

June 6, 2025 | biopharmadive.com

RegeNXBio shares fall, despite positive new data on RGX-202

June 6, 2025 | thepharmaletter.com

Regenxbio’s Duchenne gene therapy data positive as shares falter

June 5, 2025 | bioworld.com

Regenxbio Fails To Best Sarepta’s Elevidys With New Data for DMD Gene Therapy

June 5, 2025 | biospace.com

REGENXBIO updates Phase 1/2 data for Duchenne candidate

June 5, 2025 | msn.com

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

June 5, 2025 | benzinga.com

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

June 5, 2025 | prnewswire.com

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

June 5, 2025 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Shares Up 13.5% - Still a Buy?

June 3, 2025 | marketbeat.com

Short Interest in REGENXBIO Inc. (NASDAQ:RGNX) Expands By 21.9%

June 3, 2025 | marketbeat.com

Bank of America Corp DE Reduces Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

June 3, 2025 | marketbeat.com

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

June 2, 2025 | prnewswire.com

Two Sigma Advisers LP Acquires 112,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

June 1, 2025 | marketbeat.com

Two Sigma Investments LP Acquires 263,495 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

June 1, 2025 | marketbeat.com

FY2026 EPS Estimates for REGENXBIO Increased by Analyst

May 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHST, PRTC, ORKA, and RGNX Company Descriptions

BioHarvest Sciences NASDAQ:BHST

$7.20 -0.46 (-6.01%)

As of 06/13/2025 04:00 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Oruka Therapeutics NASDAQ:ORKA

$12.56 -0.31 (-2.41%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$12.58 +0.02 (+0.16%)

As of 06/13/2025 04:04 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

PureTech Health NASDAQ:PRTC

$19.61 +0.36 (+1.87%)

Closing price 06/13/2025 09:30 AM Eastern

Extended Trading

$19.61 0.00 (0.00%)

As of 06/13/2025 04:04 PM Eastern

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

REGENXBIO NASDAQ:RGNX

$9.27 -0.93 (-9.12%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$9.22 -0.04 (-0.49%)

As of 06/13/2025 07:10 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time